Laboratory Corporation of America Holdings, Inc. or Labcorp LH recently launched a new blood test that detects phosphorylated tau 217 (pTau217) — a biomarker for Alzheimer's disease. Labcorp's pTau217 ...
A blood test shows significant promise for predicting the earliest stages of Alzheimer's disease, even decades before symptoms show up. New research led by a team from Mass General Brigham in the US ...
The Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio is the first blood test aiding Alzheimer's diagnosis by detecting amyloid plaques, offering a less invasive alternative to PET scans. The test ...
The U.S. Food and Drug Administration cleared the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer’s disease. It’s got quite the name. The Lumipulse G pTau217/ß-Amyloid ...
A growing literature suggests that plasma levels of tau phosphorylated at amino acid 217 (pTau217) performs similarly to cerebrospinal fluid (CSF) biomarkers and PET imaging to detect amyloid ...
Data Across 29 Presentations Highlights Precision, Accessibility and Platform-Agnostic Adoption, Establishing ALZpath's Proprietary pTau217 as a Highly Accurate Industry Benchmark CARLSBAD, Calif., ...
Laboratory Corporation of America Holdings expanded its blood biomarker test portfolio for Alzheimer’s disease, making its pTau217 test available by prescription in the U.S. as well as for research ...
The MarketWatch News Department was not involved in the creation of this content. Data Across 29 Presentations Highlights Precision, Accessibility and Platform-Agnostic Adoption, Establishing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results